CCR9 and pancreatic adenocarcinoma: Similarly, HLA-matched TIL cultures (TIL 53) from pancreatic adenocarcinoma patients recognized and lysed PANC-1 pancreatic cancer cells more effectively upon CCR9 knockdown as shown in Fig4G, stressing that CCR9-mediated immune suppression may be a clinically relevant phenomenon in multiple tumor entities.